Twist Bioscience and Astellas have entered into a research collaboration and exclusive option license agreement to identify potential therapeutic antibodies which would help to reduce tumor microenvironment-mediated immunosuppression.
A study from the Icahn School of Medicine at Mount Sinai shows how cancer can fool immune cells, which normally repair the body, into actually helping develop the disease.
While a failed ebola drug helped treat hospitalized Covid-19 patients, the common cold virus could become key in treating advanced unresectable cancers.
Novartis AG’s Sandoz division struck a deal with Taiwan’s EirGenix Inc. to market a biosimilar version of Roche’s Herceptin that is in late-stage development to treat some cancer tumors.
